Since 2015, Leaps by Bayer has invested over $1.5 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.
from treatment to cure / prevention
Modern medicine has been pivotal in doubling life expectancy over the last 150 years. We believe it is our responsibility to not only pursue biomedical innovations that could disrupt our core business, but to transform the lives of millions of patients for the better.
from more to better
Agriculture today is optimized for the scale of a growing population. Next-generation technologies need to produce better food, better use of land and resources, better nutrition, better sustainability, better solutions for the diverse needs of people and our planet.
Our impact investment approach aims to conquer ten huge challenges facing humanity. Some people call them impossible. We call them “Leaps”.
For the long term,
we need to think big
The scale of our mission requires significant and sustained investment of both money and time. We collaborate with the world’s brightest minds in biotech and agriculture, focusing on medium-to-large equity investments over a minimum time of three to five years. Leaps by Bayer is able to provide significant early-stage funding, allowing companies to focus on the long-term delivery of their disruptive technology, rather than short-term and lower impact results.
Through our investments, we form targeted collaborations and new ventures, lift their talent towards a greater purpose, and maximize their probability of success. We accelerate the work of leading entrepreneurs with funding and active incubation to enable breakthrough ideas that achieve maturity and scale.
Currently industry convention blocks innovation by keeping IP siloed. We believe this can hinder scientific breakthroughs. We challenge this convention by enabling the exchange of proprietary assets. This can include sharing our own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. All of the companies we partner with remain autonomous with respect to decision making, we build our relationship from start to finish. Together, we aim to transform the lives of millions of patients and the health of the planet for the better.
We do so by facilitating and supporting them in a process we call “active incubation”. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction.
It is vital impact funds measure success beyond financial ROI. At Leaps, we have a key metric of success called “return for humanity”. We predict and measure if our investments improve wellbeing.
Introducing Wellbeing Adjusted Life Years (WALY), a common currency of impact based on evidence and experience.
How much happiness could we create by resolving Parkinson’s disease? Or ensuring crop shortages are less severe? WALYs provides answers.
When a catastrophe occurs, we’d previously look at ‘lives lost’ or the ‘financial cost of repair’ to determine impact. But what if no lives were lost but the event still has a meaningful impact on humanity?
WALYs provides a metric for determining the impact events have on wellbeing. It also predicts how much good for humanity we could generate by addressing disease and solving issues.